07 April 2026
Pure Global: Brazil's New SaMD Rules, Unlocking the AI MedTech Backdoor
LATAM MedTech Insights
About
Brazil just rewrote the rules for digital health. Last week, ANVISA published its new regulatory framework for Software as a Medical Device (SaMD), creating an urgent new landscape for MedTech companies. This update introduces a new risk classification system, expedited pathways for some devices, and significant new hurdles for high-risk AI and machine learning technologies.
This episode of LATAM MedTech Insights unpacks the critical details of this regulatory shift. We explore the specific requirements that international companies must meet, including the complex pre-approval process for algorithm changes and the stringent new data privacy rules tied to Brazil's LGPD. For companies in the digital health space, understanding these changes is not just important, it's essential for survival and success in Latin America's largest market.
**Key Takeaways From This Episode:**
* How does Brazil's new four-tier risk classification for SaMD differ from the FDA and MDR frameworks?
* What is an 'Algorithm Change Protocol' and why is it now a mandatory submission for AI-driven devices?
* Are there new data localization requirements under the updated cybersecurity rules?
* Which types of SaMD can now benefit from an expedited registration pathway?
* How will ANVISA's new rules impact the use of foreign clinical data in submissions?
* What are the immediate compliance risks for devices already on the Brazilian market?
* Why is a local representative more critical than ever under this new framework?
**Unlock Global Markets with Pure Global**
Navigating complex regulatory shifts like Brazil's new SaMD framework is where Pure Global excels. We provide end-to-end regulatory consulting for MedTech and IVD companies, leveraging local expertise and advanced AI tools to streamline global market access. From initial strategy and technical dossier submission to post-market surveillance and local representation, we are your partner in over 30 markets worldwide. Don't let regulatory hurdles slow your growth. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn how we can secure your entry into the LATAM market and beyond.
This episode of LATAM MedTech Insights unpacks the critical details of this regulatory shift. We explore the specific requirements that international companies must meet, including the complex pre-approval process for algorithm changes and the stringent new data privacy rules tied to Brazil's LGPD. For companies in the digital health space, understanding these changes is not just important, it's essential for survival and success in Latin America's largest market.
**Key Takeaways From This Episode:**
* How does Brazil's new four-tier risk classification for SaMD differ from the FDA and MDR frameworks?
* What is an 'Algorithm Change Protocol' and why is it now a mandatory submission for AI-driven devices?
* Are there new data localization requirements under the updated cybersecurity rules?
* Which types of SaMD can now benefit from an expedited registration pathway?
* How will ANVISA's new rules impact the use of foreign clinical data in submissions?
* What are the immediate compliance risks for devices already on the Brazilian market?
* Why is a local representative more critical than ever under this new framework?
**Unlock Global Markets with Pure Global**
Navigating complex regulatory shifts like Brazil's new SaMD framework is where Pure Global excels. We provide end-to-end regulatory consulting for MedTech and IVD companies, leveraging local expertise and advanced AI tools to streamline global market access. From initial strategy and technical dossier submission to post-market surveillance and local representation, we are your partner in over 30 markets worldwide. Don't let regulatory hurdles slow your growth. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn how we can secure your entry into the LATAM market and beyond.